Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ophiobolin A C21-methyl ketone
- Development stage
- Preclinical
- Lead developer
- Texas State University
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
Ophiobolin A C21-methyl ketone is a synthetic derivative of the fungal metabolite ophiobolin A, developed to explore the structure-activity relationship of the C21-aldehyde group. Ophiobolin A, naturally produced by Bipolaris species, is known to induce paraptosis—a non-apoptotic form of programmed cell death—in glioblastoma (GBM) cells and glioma stem cells (GSCs). The C21-methyl ketone was synthesized by reacting ophiobolin A with Grignard reagents followed by oxidation, aiming to improve metabolic stability by replacing the potentially labile aldehyde group. However, research presented at SNO 2025 indicates that this modification results in inferior cytotoxic potency against patient-derived GSCs compared to the parent compound, suggesting that steric bulk at the C21 position is detrimental to activity.
- Other names
- C21-methyl ophiobolin AC-21-methyl ophiobolin AC 21-methyl ophiobolin AC21-Me ketone of ophiobolin AC-21-Me ketone of ophiobolin AC 21-Me ketone of ophiobolin A
02
Targets
CaM (Calmodulin)COX5A (Cytochrome c oxidase subunit 5A, mitochondrial)
Beyond the preview
Go deeper on ophiobolin A C21-methyl ketone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ophiobolin A C21-methyl ketone.